BridgeBio Net Income From Continuing Ops from 2010 to 2026
| BBOT Stock | 13.10 0.00 0.00% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -66.8 M | Current Value -70.2 M | Quarterly Volatility 2.6 M |
Check BridgeBio Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BridgeBio Oncology's main balance sheet or income statement drivers, such as Selling General Administrative of 6 M, Other Operating Expenses of 97.6 M or Total Operating Expenses of 97.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.87. BridgeBio financial statements analysis is a perfect complement when working with BridgeBio Oncology Valuation or Volatility modules.
BridgeBio | Net Income From Continuing Ops | Build AI portfolio with BridgeBio Stock |
Latest BridgeBio Oncology's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of BridgeBio Oncology Therapeutics over the last few years. It is BridgeBio Oncology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BridgeBio Oncology's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
BridgeBio Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (65,711,669) | |
| Coefficient Of Variation | (3.97) | |
| Mean Deviation | 1,667,926 | |
| Median | (64,699,000) | |
| Standard Deviation | 2,610,460 | |
| Sample Variance | 6.8T | |
| Range | 9.6M | |
| R-Value | (0.55) | |
| Mean Square Error | 5.1T | |
| R-Squared | 0.30 | |
| Significance | 0.02 | |
| Slope | (285,349) | |
| Total Sum of Squares | 109T |
BridgeBio Net Income From Continuing Ops History
About BridgeBio Oncology Financial Statements
BridgeBio Oncology shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although BridgeBio Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in BridgeBio Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on BridgeBio Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -66.8 M | -70.2 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BridgeBio Stock Analysis
When running BridgeBio Oncology's price analysis, check to measure BridgeBio Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Oncology is operating at the current time. Most of BridgeBio Oncology's value examination focuses on studying past and present price action to predict the probability of BridgeBio Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Oncology's price. Additionally, you may evaluate how the addition of BridgeBio Oncology to your portfolios can decrease your overall portfolio volatility.